Oculis Holding AG (OCS) Other financing activities (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Other financing activities of $614239.3 for Q1 2026, up 75.88% year-over-year from $349246.7 in Q1 2025, and up 102.03% quarter-over-quarter from $304034.3 in Q4 2025.
Oculis Holding AG (OCS) Other financing activities (2022 - 2026) Analysis & Trends
Oculis Holding AG's Other financing activities history runs 5 years deep, the most recent figure standing at $614239.3 for Q1 2026.
- In Q1 2026, Other financing activities rose 75.88% year-over-year to $614239.3; the TTM figure through Mar 2026 stood at $2.5 million (up 117.07% YoY), while the FY2025 annual figure was $2.3 million, up 114.48% from the prior year.
- Other financing activities for Q1 2026 stood at $614239.3, up from $304034.3 in the prior quarter.
- The five-year high for Other financing activities was $1.6 million in Q2 2025, with the low at -$398517.7 in Q3 2023.
- The 5-year median for Other financing activities is $203867.5 (2023), against an average of $310164.4.
- Peak annual rise in Other financing activities reached 3929.48% in 2025, while the deepest fall reached 98.02% in 2025.
- Oculis Holding AG's Other financing activities stood at $8304.2 in 2022, then surged by 1692.0% to $148810.8 in 2023, then plunged by 42.47% to $85614.1 in 2024, then jumped by 255.12% to $304034.3 in 2025, then jumped by 102.03% to $614239.3 in 2026.
- Business Quant data shows OCS's Other financing activities at $614239.3 in Q1 2026, $304034.3 in Q4 2025, and $13751.2 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 614,239.25 |
| Mar 31, 2026 | 614,239.25 |
| Dec 31, 2025 | 304,034.26 |
| Dec 31, 2025 | 304,034.26 |
| Sep 30, 2025 | 13,751.20 |
| Sep 30, 2025 | 13,751.20 |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 349,246.67 |
| Mar 31, 2025 | 349,246.67 |
| Dec 31, 2024 | 85,614.14 |
| Dec 31, 2024 | 85,614.14 |
| Sep 30, 2024 | 693,678.55 |
| Sep 30, 2024 | 693,678.55 |
| Jun 30, 2024 | 39,808.57 |
| Jun 30, 2024 | 39,808.57 |
| Mar 31, 2024 | 258,924.20 |
| Mar 31, 2024 | 258,924.20 |
| Dec 31, 2023 | 148,810.79 |
| Dec 31, 2023 | 148,810.79 |